Clinical trial
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma
NCT00005052 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Unknown status
Key facts
| NCT number | NCT00005052 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Primary Stage II Melanoma |
| Official title | Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Procedure |
| Interventions | GM2-KLH vaccine, QS21, adjuvant therapy |
| Start date | Dec 1, 1999 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 9, 2009 |
| Countries | Australia, Belgium, Denmark, Estonia, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland and 6 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: